降脂软脉片合非洛地平治疗原发性高血压病的临床疗效研究

The Clinical Efficacy of Plendil and Jiangzhiruanmai Tablets in Patients with Essential Hypertension

目的评价服用非洛地平合降脂软脉片治疗原发性高血压病患者的降压疗效、症状疗效以及对胰岛素抵抗的改善状况,同时探讨高血压病肥胖患者和胰岛素抵抗的关系。方法采用开放研究设计。治疗组和对照组各30例。治疗组服用非洛地平2.5 mg,1次/d,降脂软脉片6片,3次/d;对照组单纯服用非洛地平2.5 mg,1次/d,疗程28 d。观察两组的降压疗效、症状疗效和对胰岛素抵抗的改善状况。结果两组服药后均可使收缩压和舒张压下降,两组均在给药后1周达到降压高峰。治疗组和对照组之间症状疗效有极显著性差异(P<0.01)。与正常体重组比较,高血压肥胖组体重指数、空腹胰岛素和胰岛素抵抗指数差异有显著性(P<0.05或P<0.01)。结论非洛地平合降脂软脉片治疗原发性高血压病的降压疗效和症状疗效均优于单纯非洛地平,尤其在症状疗效方面显示了其较好的优势;肥胖是引起高血压病患者胰岛素抵抗的因素之一,说明改善患者的胰岛素抵抗需要进行综合治疗,而不能单纯地降低血压。

Objective To assess the antihypertensive effect , symptom, safety and insulin resistance of felodipine sustained release tablets and jiangzhimanmai tablets in treatment of essential hypertension（EH） for four weeks and to investigate the relationship between the hypertensive and obesity patients and insulin resistance（IR）. Methods An open -labeled study was conducted. Thirty patients in sixty with systolic blood pressure（SBP） were treated with felodipine sustained release tablets and Jiangzhimanmai tablests the dosage of felodipine sustained release tablets was one tablet（2.5 mg） per day ,and the dosage of jiangzhiruanmai tablets was six tablets per time, three times per day. Other thirty patieny patients were only treated with felodipine sustained release tablests,the dosage was 2.5 mg per day. The antihypertensive effect and symptom effect and IRS effect were observed. Results Compare with the baseline afterweard ,the SBP and DBP of treatment group and control group singifieantly decreased after taking medicines. The antihypertensive peak of two group is after on week. Significant difference was found between treatment group and control HOMA -IR in the obesity group is higher than those in normal body weight group and significant difference was found （p 〈 0. 05 ,p 〈 0.01 ） Conclusion （ 1 ） Felodipine sustained release tablets and Jiangzhiruanmai tablets in treatment of hypertension is better than only felodipine sustained release tablets, especially in the improve of symptom. Jiangzhiruanmai tablets has remarkable advantage in improving symptom of patients with hypertension. （2） The obesity is one of factors in inducing HOMA - IR with EH.